Lykos’ MDMA therapy to go before FDA committee; GSK expands work with BioVersys

Plus, news about Eledon and Travere Therapeutics:

Lykos Therapeutics’ MDMA therapy gets an adcomm date: An FDA advisory committee is scheduled to meet June 4 to weigh the benefits and risks of the biotech’s NDA for its midomafetamine (MDMA) capsules in combination with psychological intervention for adults with post-traumatic stress disorder (PTSD). This will be the first adcomm meeting to review a new PTSD treatment in 25 years. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely

August 2, 2024

Early autism diagnosis breakthrough: machine learning uses eye movements on real and artificial faces

An innovative autism spectrum disorder (ASD) detection technique for children by examining eye movement.

September 19, 2023

FDA Rejects Full Approval of Liver Disease Drug

The FDA declined to grant full approval to obeticholic acid (Ocaliva) for treating primary biliary cholangitis (PBC), Intercept Pharmaceuticals announced on Tuesday. The decision follows

November 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.